Phase 3 trial launches of ArteraAI Prostate test for treatment selection
Clinical trial aims to guide doctors in selecting the most effective treatments that minimize the impact on quality of life w [...]
Tempus Partners with Artera to Expand Personalized Prostate Cancer Treatment
Tempus will now offer the ArteraAI Prostate Test to cancer centers across the U.S. SAN FRANCISCO--(BUSINESS WIRE)--Artera, th [...]
Artera’s Multimodal Artificial Intelligence Named Among TIME’s 2024 Best Inventions
The prestigious recognition highlights Artera’s innovation and impact in advancing the personalization of prostate cancer tre [...]
Artera Receives California Lab License, Expanding Access to its ArteraAI Prostate Test
Clinicians and patients in California can now access personalized, actionable insights to inform prostate cancer treatment de [...]
Artera Announces Two Presentations at ASTRO 2024 Validating its MMAI Platform to Inform Treatment Decisions for Oligometastatic Castration-Sensitive Prostate Cancer (omCSPC)
Data demonstrates the multimodal artificial intelligence (MMAI) biomarker’s ability to prognosticate and predict the therapeu [...]
Artera Announces Expansion of the ArteraAI Prostate Test to Inform Active Surveillance Decisions for Lower Risk Prostate Cancer Patients
The test report now provides personalized insights for prostate cancer patients considering active surveillance SAN FRANCISCO [...]
Artera Announces Three Presentations at ASCO 2024 That Demonstrate the Reliability and Depth of its AI Cancer Platform
The significant scalability of Artera’s groundbreaking multimodal AI platform is showcased with abstracts in advanced stages [...]
New Data Validating the First AI-Based Biomarker to Stratify Risk of Metastasis in Radical Prostatectomy Patients with Biochemical Recurrence
Results identified 40% of BCR patients who benefited from therapy intensification vs. 60% of patients who did not The data re [...]
ArteraAI and Movember Announce New Relationship
Harnessing AI to accelerate personalized cancer treatment SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimod [...]